Laila A Abou-Zeid

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3354984/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Docking studies, antitumor and antioxidant evaluation of newly synthesized porphyrin and metalloporphyrin derivatives. Dyes and Pigments, 2020, 183, 108728.	2.0	14
2	1,2,3-Triazole-Chalcone hybrids: Synthesis, inÂvitro cytotoxic activity and mechanistic investigation of apoptosis induction in multiple myeloma RPMI-8226. European Journal of Medicinal Chemistry, 2020, 189, 112062.	2.6	49
3	Synthesis and Computational Analysis of New Antioxidant and Antimicrobial Angular Chromenopyrimidines. Journal of Heterocyclic Chemistry, 2019, 56, 2922-2933.	1.4	12
4	Synthesis, Biological Evaluation and In Silico Studies of 1,2,4â€Triazole and 1,3,4â€Thiadiazole Derivatives as Antiherpetic Agents. ChemistrySelect, 2019, 4, 6421-6428.	0.7	12
5	New approach for the synthesis, docking of new porphyrins and their antitumor activity. Journal of Porphyrins and Phthalocyanines, 2019, 23, 251-259.	0.4	5
6	Design, synthesis and docking study of novel picolinamide derivatives as anticancer agents and VEGFR-2 inhibitors. European Journal of Medicinal Chemistry, 2019, 168, 315-329.	2.6	54
7	Synthesis, biological evaluation and in silico molecular docking of novel 1-hydroxy-naphthyl substituted heterocycles. Saudi Pharmaceutical Journal, 2018, 26, 852-859.	1.2	14
8	Synthesis, Biological Evaluation, and Molecular Docking Studies of Novel Pyrazolo[3,4â€ <i>d</i>]pyrimidines as Potential Telomerase Inhibitors. Journal of Heterocyclic Chemistry, 2018, 55, 803-813.	1.4	4
9	Synthesis, antitumour activities and molecular docking of thiocarboxylic acid ester-based NSAID scaffolds: COX-2 inhibition and mechanistic studies. Journal of Enzyme Inhibition and Medicinal Chemistry, 2018, 33, 989-998.	2.5	25
10	Design, synthesis, molecular modeling and biological evaluation of novel diaryl heterocyclic analogs as potential selective cyclooxygenase-2 (COX-2) inhibitors. Saudi Pharmaceutical Journal, 2017, 25, 59-69.	1.2	14
11	Synthesis, anticancer and apoptosis-inducing activities of quinazoline–isatin conjugates: epidermal growth factor receptor-tyrosine kinase assay and molecular docking studies. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 935-944.	2.5	41
12	Synthesis, anti-inflammatory, analgesic, COX-1/2 inhibitory activities and molecular docking studies of substituted 2-mercapto-4(3H)-quinazolinones. European Journal of Medicinal Chemistry, 2016, 121, 410-421.	2.6	81
13	Design, synthesis of 2,3-disubstitued 4(3H)-quinazolinone derivatives as anti-inflammatory and analgesic agents: COX-1/2 inhibitory activities and molecular docking studies. Bioorganic and Medicinal Chemistry, 2016, 24, 3818-3828.	1.4	70
14	Synthesis, anti-inflammatory, analgesic and COX-1/2 inhibition activities of anilides based on 5,5-diphenylimidazolidine-2,4-dione scaffold: Molecular docking studies. European Journal of Medicinal Chemistry, 2016, 115, 121-131.	2.6	50
15	DNA binding of ethyl 2-substituted aminothiazole-4-carboxylate analogues: A molecular modeling approach to predict their antitumor activity. Future Journal of Pharmaceutical Sciences, 2015, 1, 1-7.	1.1	2
16	Thermal stability of G-rich anti-parallel DNA triplexes upon insertion of LNA and α- <scp> </scp> -LNA. Organic and Biomolecular Chemistry, 2015, 13, 5115-5121.	1.5	4
17	Combating oxidative stress as a hallmark of cancer and aging: Computational modeling and synthesis of phenylene diamine analogs as potential antioxidant. Saudi Pharmaceutical Journal, 2014, 22, 264-272.	1.2	6
18	Synthesis and biological evaluation of new curcumin derivatives as antioxidant and antitumor agents. Medicinal Chemistry Research, 2013, 22, 1147-1162.	1.1	45

Laila A Abou-Zeid

#	Article	IF	CITATIONS
19	Highly Efficient Synthesis of Allopurinol Locked Nucleic Acid Monomer by C6 Deamination of 8-Aza-7-bromo-7-deazaadenine Locked Nucleic Acid Monomer. Synthesis, 2013, 45, 3259-3262.	1.2	2
20	Computational Modeling, Synthesis, and Antioxidant Potential of Novel Phenylcarbamoylbenzoic Acid Analogs in Combating Oxidative Stress. Archiv Der Pharmazie, 2012, 345, 902-910.	2.1	7
21	Synthesis, antiplatelet aggregation activity, and molecular modeling study of novel substituted-piperazine analogues. Medicinal Chemistry Research, 2011, 20, 898-911.	1.1	11
22	Non-classical antifolates. Part 2: Synthesis, biological evaluation, and molecular modeling study of some new 2,6-substituted-quinazolin-4-ones. Bioorganic and Medicinal Chemistry, 2010, 18, 2849-2863.	1.4	121
23	Therapeutic and Toxic Effects of New NSAIDs and Related Compounds: A Review and Prospective Study. International Journal of Pharmacology, 2010, 6, 813-825.	0.1	22
24	Synthesis, dihydrofolate reductase inhibition, antitumor testing, and molecular modeling study of some new 4(3H)-quinazolinone analogs. Bioorganic and Medicinal Chemistry, 2006, 14, 8608-8621.	1.4	171
25	Progesterone inhibition of MDM2 p90 protein in MCF-7 human breast cancer cell line is dependent on p53 levels. Journal of Molecular and Genetic Medicine: an International Journal of Biomedical Research, 2005, 01, 33-7.	0.1	2
26	Differential recognition of resveratrol isomers by the human estrogen receptor-?: Molecular dynamics evidence for stereoselective ligand binding. Chirality, 2004, 16, 190-195.	1.3	28
27	Recognition of Resveratrol by the Human Estrogen Receptor-Alpha: A Molecular Modeling Approach to Understand Its Biological Actions. Medical Principles and Practice, 2002, 11, 86-92.	1.1	16
28	Molecular dynamics simulation characteristics of resveratrol interaction with human estrogen receptor-α: distinct recognition from diethylstilbestrol. Computational and Theoretical Chemistry, 2002, 593, 39-48.	1.5	9
29	Synthesis, spectroscopic characterization, stability assessment and DNA-binding of new 2,6-piperidinedione derivatives. Il Farmaco, 2001, 56, 763-770.	0.9	10
30	Novel Piperidinedione Analogs as Inhibitors of Breast Cancer Cell Growth. Archiv Der Pharmazie, 2000, 333, 431-434.	2.1	4
31	Potential utility of antineoplaston A-10 levels in breast cancer. Cancer Letters, 2000, 155, 67-70.	3.2	13
32	Immune modulatory potentials of antineoplaston A-10 in breast cancer patients. Cancer Letters, 2000, 157, 57-63.	3.2	13